Business
Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
CUPERTINO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage
About this update from Reviva Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"CUPERTINO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will both present and participate in a conference panel at the H.C. Wainwright 25th Annual Global Investment Conference, taking place September 11-13, 2023 virtually and in New York City, New York. H.C. Wainwright 25th Annual Global Investment Conference Format: Corporate updateDate/Time: Pre-recorded presentation available on-demand Monday, September 11 at 1:30 p.m. ETLocation: Virtual and Lotte New York Palace HotelWebcast Link: Click Here Format: Conference panel: Emerging Therapies and Future Directions in SchizophreniaDate/Time: Tuesday, September 12 at 3:30 p.m. ETLocation: Virtual and Lotte New York Palace Hotel Management will also be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact your H.C. Wainwright sales representative to register for the conference. About Brilaroxazine Brilaroxazine is an in-house discovered new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia and its comorbid symptoms. In a multinational, multicenter, double-blind Phase 2 study in 234 patients with acute schizophrenia or schizoaffective disorder, brilaroxazine met its primary endpoint, reducing Positive and Negative Syndrome Scale (PANSS) total score and demonstrating statistically significant improvement of overall drug treatment outcomes using Clinical Global Impression (CGI) scale and for secondary endpoints evaluating social functioning, and positive and negative symptoms, and directional improvements for depression and cognition. In this completed Phase 2 study, brilaroxazine met all safety endpoints with no weight gain, no increase in blood sugar and lipids, and no cardiac or endocrine adverse effects compared to placebo. Positive data from a clinical drug-drug interaction (DDI) study investigating the potential effect of CYP3A4 enzyme on brilaroxazine in healthy subjects supports no clinically s...